GeoVax Labs Inc. (NASDAQ:GOVX) Sees Significant Decline in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 272,648 shares, a decline of 15.2% from the January 29th total of 321,661 shares. Approximately 15.0% of the company’s shares are sold short. Based on an average daily trading volume, of 124,907 shares, the short-interest ratio is currently 2.2 days. Based on an average daily trading volume, of 124,907 shares, the short-interest ratio is currently 2.2 days. Approximately 15.0% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GOVX. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a report on Saturday, January 17th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $187.50.

Hedge Funds Weigh In On GeoVax Labs

Several institutional investors and hedge funds have recently modified their holdings of GOVX. Jane Street Group LLC acquired a new position in shares of GeoVax Labs in the first quarter worth about $27,000. Hudson Bay Capital Management LP acquired a new stake in GeoVax Labs during the 3rd quarter worth $47,000. HRT Financial LP purchased a new stake in GeoVax Labs during the 4th quarter valued at about $31,000. Armistice Capital LLC purchased a new stake in shares of GeoVax Labs in the third quarter valued at approximately $253,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at approximately $104,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Stock Performance

Shares of GeoVax Labs stock opened at $1.74 on Friday. The company has a 50-day simple moving average of $2.87 and a two-hundred day simple moving average of $9.76. The company has a market capitalization of $3.17 million, a PE ratio of -0.05 and a beta of 3.81. GeoVax Labs has a one year low of $1.26 and a one year high of $47.13.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.